Preferences for a potential longer-acting injectable contraceptive: perspectives from women, providers, and policy makers in Kenya and Rwanda

Figures & Tables

TABLE 1. Composition of Focus Group Discussions Among Potential Users of a Longer-Acting Injectable, by Country

FGD Number	Location	Facility Type	Experience With Injectable Use	No. of Participants	Mean Age (Range)
Kenya
1	Urban	Public health center	Current and past users	10	28.1 (21–38)
2	Urban	Public health center	Never users	8	36.7 (18–45)
3	Peri-urban	Public hospital	Current and past users	11	27.7 (21–37)
4	Peri-urban	Public health center	Current and past users	8	25.2 (20–32)
5	Urban	NGO health center	Current and past users	10	31.0 (23–40)
6	Urban	NGO health center	Current and past users	8	29.4 (25–37)
7	Urban	NGO health center	Never users	9	30.3 (23–36)
8	Peri-urban	Public health center	Current and past users	10	29.9 (22–40)
9	Peri-urban	Public health center	Current and past users	11	29.4 (25–38)
10	Peri-urban	Public hospital	Never users	8	31.6 (20–42)
Total				93
Rwanda
1	Rural	Public CBD	Current, past, and never users	10	32.4 (24–50)
2	Rural	Public health center	Current and past users	7	30.7 (26–39)
3	Peri-urban	Public health center	Never users	13	28.0 (20–39)
4	Urban	Public hospital	Never and past users	11	28.4 (21–37)
5	Rural	Public CBD	Current users	8	37.7 (28–44)
6	Rural	Public health center	Current and past users	9	31.3 (21–40)
7	Rural	Public CBD	Current and past users	9	34.8 (21–44)
8	Urban	Public hospital	Current users	7	28.6 (22–35)
9	Urban	NGO health center	Current, past, and never users	10	31.9 (25–44)
Total				84

TABLE 2. Three Most and Least Important Attributes of a Potential Longer-Acting Injectable, by Participant Type and Country^a

Attributes	Most Important						Least Important
	Potential Users		Providers		Policy Makers		Potential Users		Providers		Policy Makers
	Kenya	Rwanda	Kenya	Rwanda	Kenya	Rwanda	Kenya	Rwanda	Kenya	Rwanda	Kenya	Rwanda
99% effective	1	2	1	2	1	1
Safe for BF and new mothers	3	1		2
Immediate return to fertility	2		2		3			2				2
Storage without refrigeration				1							3
Prepackaged, single dose, disposable	3	2				2
Cost around US$4/year			3	2		2	2	1			3
Side effects no worse than current methods	3		3	3	2			3
Suitable for all women		3		3	3	3	3
6-month duration with 1-month window									3	2	2	3
Can be administered in arm							3	3	1	3	1	1
Can be provided by CBD							1	1	2	1

Abbreviations: BF, breastfeeding; CBD, community-based distribution.
↵a In Kenya, rankings are among 10 groups of potential users, 15 providers, and 12 policy makers. In Rwanda, rankings are among 9 groups of potential users, 12 providers, and 7 policy makers.